TNF is a human gene. Variants in TNF have been implicated in Juvenile Myoclonic Epilepsy (JME), Alzheimer's Disease, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Gene Function
BRD2 encodes a BET (Bromodomain and Extra-Terminal domain) family transcriptional regulator that reads acetylated histones and recruits transcriptional machinery to active chromatin. BRD2 is located within the major histocompatibility complex (MHC) class II region on chromosome 6p21.3 and plays critical roles in neural development, cell cycle regulation, and inflammatory gene expression.
BRD2 contains:
Bromodomain 1 (BD1): Preferentially binds di-acetylated H4 (H4K5acK12ac), a mark enriched at gene promoters during active transcription
Bromodomain 2 (BD2): Binds acetylated H4K5/K8/K12 with broader specificity, contributing to chromatin association during different transcriptional states
ET domain: Mediates protein-protein interactions with transcription factors, including recruitment of the Mediator complex and transcriptional elongation factors
SEED domain: BRD2-specific domain that interacts with E2F transcription factors, linking histone acetylation to cell cycle gene expression
BRD2 functions in neural biology through:
Transcriptional coactivation: BRD2 bridges acetylated chromatin to the transcriptional machinery, facilitating expression of neural-specific genes including ion channels, neurotransmitter receptors, and synaptic proteins
Cell cycle regulation: BRD2 interacts with E2F1/E2F2 to drive expression of cyclins and CDKs required for neural progenitor proliferation; BRD2 heterozygous knockout mice show reduced neural tube cell proliferation
GABAergic neuron development: BRD2 is essential for specification and maturation of GABAergic interneurons. BRD2 haploinsufficiency reduces GABAergic neuron density, providing a direct mechanistic link to epilepsy
Inflammatory regulation: BRD2 co-activates [NF-κB](/entities/nf-kb)-dependent inflammatory gene expression; in [microglia](/cell-types/microglia-neuroinflammation), BRD2 occupies promoters of [IL-6](/genes/il6), [TNF](/genes/tnf), and [CCL2](/genes/ccl2)
Chromatin bookmarking: During mitosis, BRD2 remains associated with specific gene promoters, enabling rapid transcriptional reactivation upon mitotic exit — a function critical for maintaining neural progenitor identity
Neural Expression and Brain Distribution
BRD2 is highly expressed throughout the central nervous system:
[Cortex](/brain-regions/cortex): Enriched in both excitatory and inhibitory [neurons](/entities/neurons) across all cortical layers
[Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 pyramidal cells and GABAergic interneurons
Thalamus: Strong expression in thalamocortical relay neurons, consistent with roles in epileptogenesis
Cerebellum: Purkinje cell and granule cell expression
Developing brain: Critical during embryonic neurogenesis; expression peaks during E11-E15 (mouse) coinciding with interneuron specification and migration
Disease Associations
Juvenile Myoclonic Epilepsy (JME)
BRD2 is one of the best-characterized genetic risk factors for juvenile myoclonic epilepsy (JME), the most common form of idiopathic generalized epilepsy. The association arises from several lines of evidence:
Common promoter variants (including rs3918149) that reduce BRD2 expression are significantly enriched in JME patients
BRD2 heterozygous knockout mice develop spontaneous seizures and photoparoxysmal responses, closely modeling human JME
BRD2 haploinsufficiency reduces GABAergic interneuron number by 30-50% in cortex and hippocampus, creating an excitatory/inhibitory imbalance that lowers seizure threshold
The mechanism links to reduced expression of GAD67 ([GAD1](/genes/gad1)), the rate-limiting enzyme for GABA synthesis, in BRD2-deficient interneurons
Alzheimer's Disease
BRD2 contributes to [AD](/diseases/alzheimers-disease) pathogenesis through:
Neuroinflammation: BRD2 co-activates NF-κB-dependent microglial inflammatory programs; BET inhibitors (JQ1, I-BET762) reduce pro-inflammatory cytokine production in AD model microglia
[Tau](/proteins/tau) acetylation: BRD2 interacts with acetyltransferase [p300](/genes/ep300) at the [MAPT](/genes/mapt) locus; BRD2-dependent acetylation of tau at K174 and K274 promotes pathological tau aggregation
[Amyloid-beta](/proteins/amyloid-beta) response: Microglial BRD2 drives expression of inflammatory mediators in response to amyloid-beta oligomers, amplifying the neuroinflammatory cascade
Parkinson's Disease
Microglial activation: BRD2-dependent inflammatory gene expression in microglia contributes to dopaminergic neuron loss in [PD](/diseases/parkinsons-disease) models
Alpha-synuclein: BRD2 occupancy at inflammatory gene promoters is increased by [alpha-synuclein](/proteins/alpha-synuclein) fibril stimulation, suggesting a feedforward inflammatory loop
BET inhibitors: Pan-BET inhibitors (JQ1, I-BET762, OTX-015) and BD2-selective inhibitors (ABBV-744, GSK046) potently suppress neuroinflammation in preclinical AD and PD models. BD2-selective inhibitors may offer better therapeutic windows by preserving BRD2's BD1-mediated housekeeping functions
Anti-epileptic potential: Understanding BRD2's role in GABAergic specification suggests that enhancing BRD2 expression or function could increase GABAergic tone and raise seizure threshold
Neuroinflammation targeting: Selectively inhibiting BRD2's inflammatory co-activation function (without blocking its neural developmental role) could reduce chronic neuroinflammation in AD and PD
Combination strategies: BET inhibitors combined with anti-amyloid or anti-tau therapies may enhance efficacy by simultaneously targeting protein aggregation and the inflammatory response
See Also
[BRD4](/genes/brd4) — BET family, super-enhancer regulation
[Pal et al., BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy (2003) (2003)](https://doi.org/10.1086/375433)
[Velíšek et al., GABAergic neuron deficit in the Brd2+/- mouse model of juvenile myoclonic epilepsy (2011) (2011)](https://doi.org/10.1111/j.1528-1167.2011.03218.x)
[Gyuris et al., The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis (2009) (2009)](https://doi.org/10.1016/j.bbamcr.2008.09.013)
[Nicodeme et al., Suppression of inflammation by a synthetic histone mimic (2010) (2010)](https://doi.org/10.1038/nature09589)
[DeMars et al., BRD2 haploinsufficiency in mice reduces interneuron density and models photosensitive JME (2018) (2018)](https://doi.org/10.1111/epi.14491)
[Benito et al., The BET/BRD inhibitor JQ1 improves brain plasticity in a mouse model of neurodegeneration (2017) (2017)](https://doi.org/10.1016/j.trci.2017.03.003)
[LeRoy et al., The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription (2008) (2008)](https://doi.org/10.1016/j.molcel.2008.01.018)
[Magistri et al., The BET-bromodomain inhibitor JQ1 reduces neuroinflammation (2016) (2016)](https://doi.org/10.1186/s12974-016-0559-8)
[Greenberg et al., BRD2 association in idiopathic generalized epilepsy: a systematic review and meta-analysis (2016) (2016)](https://doi.org/10.1111/epi.13321)
[Denis et al., Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines (2006) (2006)](https://doi.org/10.1002/jcp.20596)